harvard bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. we sell our products to thousands of researchers in over 100 countries through our full-line catalog (and various other specialty catalogs), our websites, and through distributors, including ge healthcare, thermo fisher scientific inc., and vwr. we have sales and manufacturing operations in the united states, the united kingdom, germany, and spain and sales facilities in france and canada.
Company profile
Ticker
HBIO
Exchange
Website
CEO
James W. Green
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Biochrom Limited • Biochrom US, Inc. • CMA Microdialysis Ab • Data Sciences International, Inc. • Data Sciences (UK) Mn, Ltd. • Data Sciences GmbH • DSI (Shanghai) Trading Co Ltd. • Harvard Bioscience (Shanghai) Co. Ltd. • Hugo Sachs Elektronik - Harvard Apparatus GmbH • Multichannel Systems MCS GmbH ...
IRS number
43306140
HBIO stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
3 Apr 24
DEFA14A
Additional proxy soliciting materials
3 Apr 24
DEF 14A
Definitive proxy
3 Apr 24
8-K
Entry into a Material Definitive Agreement
3 Apr 24
8-K
Departure of Directors or Certain Officers
26 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Harvard Bioscience Announces Fourth Quarter 2023 Financial Results
7 Mar 24
8-K
Results of Operations and Financial Condition
5 Jan 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Harvard Bioscience Announces Third Quarter 2023 Financial Results
7 Nov 23
Transcripts
HBIO
Earnings call transcript
2023 Q4
7 Mar 24
HBIO
Earnings call transcript
2023 Q3
7 Nov 23
HBIO
Earnings call transcript
2023 Q2
8 Aug 23
HBIO
Earnings call transcript
2023 Q1
25 Apr 23
HBIO
Earnings call transcript
2022 Q4
9 Mar 23
HBIO
Earnings call transcript
2022 Q3
8 Nov 22
HBIO
Earnings call transcript
2022 Q2
7 Aug 22
HBIO
Earnings call transcript
2022 Q1
4 May 22
HBIO
Earnings call transcript
2021 Q4
8 Mar 22
HBIO
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
SC 13G
Leviticus Partners LP
19 Mar 24
4
Jennifer Cote
7 Mar 24
4
James W Green
7 Mar 24
SC 13G/A
Harvey Partners, LLC
14 Feb 24
SC 13G/A
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.
14 Feb 24
SC 13G/A
B. Riley Asset Management, LLC
14 Feb 24
SC 13G/A
Harvard Apparatus Regenerative Technology, Inc.
13 Feb 24
SC 13G
BlackRock Inc.
26 Jan 24
SC 13G/A
Leviticus Partners LP
22 Jan 24
4
James W Green
3 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.34 mm | 5.34 mm | 5.34 mm | 5.34 mm | 5.34 mm | 5.34 mm |
Cash burn (monthly) | (no burn) | (no burn) | 311.00 k | 181.17 k | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 2.08 mm | 1.21 mm | n/a | n/a |
Cash remaining | n/a | n/a | 3.26 mm | 4.13 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | 10.5 | 22.8 | n/a | n/a |
Institutional ownership, Q2 2023
74.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 100 |
Opened positions | 42 |
Closed positions | 6 |
Increased positions | 26 |
Reduced positions | 20 |
13F shares | Current |
---|---|
Total value | 166.49 bn |
Total shares | 32.46 mm |
Total puts | 200.00 |
Total calls | 28.20 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
272 Capital | 3.06 mm | $16.82 bn |
Punch & Associates Investment Management | 2.86 mm | $15.72 bn |
BLK Blackrock | 2.62 mm | $14.40 bn |
Harvey Partners | 2.52 mm | $13.86 bn |
AMH Equity | 2.00 mm | $10.98 bn |
Vanguard | 1.96 mm | $10.77 bn |
Dimensional Fund Advisors | 1.82 mm | $9.98 bn |
Granahan Investment Management | 1.44 mm | $7.90 bn |
Royce & Associates | 1.40 mm | $7.69 bn |
Boothbay Fund Management | 1.17 mm | $6.45 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Dec 23 | Green James W | Common Stock | Payment of exercise | Dispose F | No | No | 5.35 | 82,790 | 442.93 k | 2,651,497 |
29 Dec 23 | Jennifer Cote | Common Stock | Payment of exercise | Dispose F | No | No | 5.35 | 2,631 | 14.08 k | 107,058 |
29 Dec 23 | Jennifer Cote | Common Stock | Payment of exercise | Dispose F | No | No | 5.35 | 3,279 | 17.54 k | 109,689 |
29 Dec 23 | Green James W | Common Stock | Payment of exercise | Dispose F | No | No | 5.35 | 52,206 | 279.30 k | 2,734,287 |
29 Dec 23 | Green James W | Common Stock | Payment of exercise | Dispose F | No | No | 5.35 | 23,216 | 124.21 k | 2,786,493 |
29 Dec 23 | Green James W | Common Stock | Payment of exercise | Dispose F | No | No | 5.35 | 28,783 | 153.99 k | 2,809,709 |
29 Dec 23 | Green James W | Common Stock | Payment of exercise | Dispose F | No | No | 5.35 | 24,187 | 129.40 k | 2,838,492 |
17 Aug 23 | Green James W | Common Stock | Buy | Acquire P | No | No | 4.38 | 25,000 | 109.50 k | 2,862,679 |
11 Jun 23 | Green James W | Common Stock | Payment of exercise | Dispose F | No | No | 5.46 | 48,373 | 264.12 k | 2,837,679 |
22 May 23 | Bertrand Loy | Common Stock | Grant | Acquire A | No | No | 0 | 31,516 | 0.00 | 79,009 |
News
Harvard Bioscience Q4 Adj EPS $0.04 Misses $0.05 Estimate, Sales $28.15M Miss $29.11M Estimate
7 Mar 24
Earnings Scheduled For March 7, 2024
7 Mar 24
A Preview Of Harvard Bioscience's Earnings
6 Mar 24
Harvard Bioscience To Showcase Latest Solutions For Preclinical And Organoid Applications At Society Of Toxicology Meeting
6 Mar 24